Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge
SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson's (("J&, J's", NYSE:JNJ) Innovation Challenge. This invitation-only event seeks novel approaches to treating atopic dermatitis from around the world. Artelo was awarded th ...